News >

Biomarkers Needed to Refine Use of Novel Combos in mRCC

Brandon Scalea
Published: Wednesday, Apr 17, 2019

Neeraj Agarwal, MD

Neeraj Agarwal, MD
The combination of PD-1 inhibitors and VEGF TKIs has emerged as a promising option for the frontline treatment of patients with metastatic renal cell carcinoma (mRCC), but the lack of biomarkers and refined guidelines for patient selection remain as challenges, said Neeraj Agarwal, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x